$18.08
2.73% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
ANN6748L1027
Symbol
OFIX

Orthofix International NV Stock price

$18.08
+2.42 15.45% 1M
+2.71 17.63% 6M
+4.60 34.12% YTD
+7.36 68.66% 1Y
-13.92 43.50% 3Y
-26.84 59.75% 5Y
-10.37 36.45% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.48 2.73%
ISIN
ANN6748L1027
Symbol
OFIX
Sector

Key metrics

Market capitalization $690.91m
Enterprise Value $814.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.04
P/S ratio (TTM) P/S ratio 0.88
P/B ratio (TTM) P/B ratio 1.31
Revenue growth (TTM) Revenue growth 17.32%
Revenue (TTM) Revenue $784.25m
EBIT (operating result TTM) EBIT $-85.60m
Free Cash Flow (TTM) Free Cash Flow $-43.52m
Cash position $32.55m
EPS (TTM) EPS $-3.14
P/E forward negative
P/S forward 0.84
EV/Sales forward 1.00
Short interest 6.74%
Show more

Is Orthofix International NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Orthofix International NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Orthofix International NV forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Orthofix International NV forecast:

Buy
75%
Hold
25%

Financial data from Orthofix International NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
784 784
17% 17%
100%
- Direct Costs 268 268
9% 9%
34%
516 516
22% 22%
66%
- Selling and Administrative Expenses 470 470
8% 8%
60%
- Research and Development Expense 74 74
1% 1%
9%
-28 -28
68% 68%
-4%
- Depreciation and Amortization 58 58
25% 25%
7%
EBIT (Operating Income) EBIT -86 -86
36% 36%
-11%
Net Profit -119 -119
13% 13%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Orthofix International NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Orthofix International NV Stock News

Neutral
Business Wire
4 days ago
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Stifel 2024 Healthcare Conference in New York, NY, November 18, 2024, fireside chat at 8:35 AM Easte...
Neutral
Seeking Alpha
5 days ago
Orthofix Medical Inc. (NASDAQ:OFIX ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Iseult McMahon - BTIG Jason Wittes - ROTH MKM Operator Good morning, and welcome to the Orthofix ...
Neutral
Business Wire
9 days ago
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its full-year 2024 financial guidance, and introduced new three-year financial targets. Recent Highlights Third quarter 2024 net sales of $196.6 million, an increase of 7% on a report...
More Orthofix International NV News

Company Profile

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Head office Curaçao
CEO Massimo Calafiore
Employees 1,634
Founded 1987
Website www.orthofix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today